Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases

被引：159

作者：

Wilder, RL ^{[1
]}

机构：

[1] Medimmune Inc, Clin Dev, Gaithersburg, MD 20878 USA

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2002年 / 61卷

关键词：

D O I：

10.1136/ard.61.suppl_2.ii96

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A substantial and persuasive body of data now exists that,supports the view that integrin alpha V beta 3 plays a critical part in activated macrophage dependent inflammation, osteoclast development, migration, and bone resorption, and, inflammatory angiogenesis. All of these processes play an important part in, the pathogenesis of rheumatoid arthritis (RA), and related arthropathies. Animal arthritis model data further support these concepts and also suggest that therapeutic:antagonism of integrin alpha V beta 3 is worthy of further investigation in RA and related arthropathies. To this end, Vitaxin, also known as MEDI-522, has been developed. Vitaxin is a humanised monoclonal I(g)G(1) antibody that specifically binds a conformational epitope formed by both the integrin alpha V and beta 3 subunits. It blocks the interaction of alpha V beta 3 with various ligands such as osteopontin and vitronectin. Clinical trials with Vitaxin in patients with RA are in progress.

引用

页码：96 / 99

页数：4

共 59 条

[1]

ALBELDA SM, 1990, CANCER RES, V50, P6757

[2]

Badger AM, 2001, ARTHRITIS RHEUM-US, V44, P128, DOI 10.1002/1529-0131(200101)44:1<128::AID-ANR17>3.0.CO

[3]

2-M

[4] Cysteine-rich module structure reveals a fulcrum for integrin rearrangement upon activation [J].